Journals / Retina-Vitreus / 2009 / Cilt: 17 - Sayı: 4

Results of comparison in use to alternative therapy methods for subfoveal choroidal neovascularization secondary to age-related macular degeneration

Yaşa bağlı makula dejeneresansındaki subfoveal koroid neovaskülarizasyonların tedavisinde kullanılan alternatif yöntemlerin karşılaştırmalı sonuçları

Pages
245–250
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For decreasing the number of İVB, the combined therapies are also applied frequently in nowadays.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the efficacy of intravitreal bevacizumab (IVB) treatment, photodynamic therapy (PDT) and combination therapy in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) Material and Methods: This study included a total of 109 eyes of 88 patient with CNV secondary to AMD.
📊
Key Findings & Data:We had three groups; PDT monotherapy (group1), intravitreal bevacizumab monotherapy(group 2) and PDT with IVB combination therapy (group 3).
💡
Conclusion & Impact:For decreasing the number of İVB, the combined therapies are also applied frequently in nowadays.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Maküler dejenerasyon · Fotokemoterapi · Koroidal neovaskülarizasyon

Abstract

Purpose: To evaluate the efficacy of intravitreal bevacizumab (IVB) treatment, photodynamic therapy (PDT) and combination therapy in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) Material and Methods: This study included a total of 109 eyes of 88 patient with CNV secondary to AMD. We had three groups; PDT monotherapy (group1), intravitreal bevacizumab monotherapy(group 2) and PDT with IVB combination therapy (group 3). Best corrected visual acuity (BCVA), lesion types, remission time and macular optical coherence tomography (OCT) results were assessed. Results: The mean age was 69.65±7.98 years, the mean follow-up time was 12 months. 41 eyes of 34 patients in group 1, 32 eyes of 25 patients in group 2, 29 eyes of 36 patients in group 3 were examined. In group 2 the mean BCVA was statistically significant higher at 1 month and 12 months follow-up than pre-treatment values. In group 3 the mean BCVA was statistically significant higher only at 1 month follow-up than pre-treatment values. In group 3 the remission time was statistically significant longer than the other groups. In group 3 the mean treatment number was statistically significant lower than the group 2. Conclusion: IVB treatment seems to be safe, effective and lowcost for the CNV secondary to AMD. For decreasing the number of İVB, the combined therapies are also applied frequently in nowadays.

Özet

Amaç: Yaşa bağlı maküla dejenerasansı (YBMD) sonucu oluşan koroid neovaskülarizasyonu (KNV) tedavisinde oküler fotodinamik tedavi (FDT), intravitreal bevacizumab (İVB) ve kombine tedavinin etkinlerinin değerlendirilmesi. Gereç ve Yöntemler: Bu çalışmaya Yaşa bağlı maküla dejenerasansına bağlı gelişen koroid neovasküler membran sebebi ile tedavi edilen 88 hastanın 109 gözü dahil edildi. Hastalar sadece fotodinamik tedavi (grup 1), sadece intravitreal bevacizumab (İVB) enjeksiyon tedavisi (grup 2) ve FDT ile birlikte İVB enjeksiyon tedavisi uygulanan gözler (grup 3) olarak ayrıldı. Hastaların tedaviye verdikleri yanıt; en iyi düzeltilmiş görme keskinliği (EİDGK), flöresein anjiografi (FA) ve optik koherens tomografi (OKT) bulguları ile değerlendirildi. Bulgular: Hastaların ortalama yaşları 69.65±7.98 yıldı. Grupların 12 aylık sonuçları değerlendirildi. 1. grupta 34 hastanın 41 gözü, 2. grupta 25 hastanın 32 gözü, 3. grupta ise 29 hastanın 36 gözü incelendi. FDT gurubunda 12. ayda EİDGK anlamlı olarak daha düşüktü. İVB grubunda, EİDGK’de anlamlı olarak artış 1. ay ve 12. ayda devam etmiştir. Kombine tedavi gurubunda ise sadece 1. aydaki bu artış anlamlıydı. Kombine tedavi gurubunda ortalama nüks süresi diğer gruplara göre anlamlı olarak daha uzun bulunmuştur (p<0.05). Buna bağlı olarakta tekrar tedavi ihtiyacı en az bu grupta bulunmuştur. En fazla tedavi tekrarının İVB grubunda yapıldığı izlenmiştir. Tartışma: Çalışmamızın sonucuna göre İVB tedavisi ve kombine tedavinin görme keskinliğinin korunması açısından daha etkili olduğu bulunmuştur. Ayrıca YBMD zemininde gelişen KNV olgularında kombine tedavinin erken dönemde monoterapiye göre nüks sıklığı ve görme keskinliği açısından daha etkili ve güvenilir olduğu görülmektedir.

🔖

Cite This Article

ERDOKUR, O., TETİKOĞLU, M., ÖZTÜRK, M., ELÇİOĞLU, M. (2009). Results of comparison in use to alternative therapy methods for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina-Vitreus, Cilt: 17 - Sayı: 4, 245–250. https://ajindex.com/articles/305211

References (14)

  1. Young RW.: Pathophysiology of age-related macular degeneration. Surv. Opthalmol. 1987;31:291-306
  2. Bird AC, Bressler NM, Bressler SB, et al.: An international classification and grading system for age-related maculopathy and agerelated macular degeneration. Surv Ophthalmol. 1995;39:367- 374
  3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group: Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report No
  4. Arch Ophthalmol. 2003;121:1253-1268
  5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials-TAP Report no
  6. Arch Ophthalmol. 2002;120:1307-1314
  7. Verteporfin In Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--Verteporfin in Photodynamic Therapy (VIP) report 2. Am J Ophthalmol. 2001;131:541-560
  8. Ng EW, Adamis AP: Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352-368
  9. VEGF Inhibiton Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular agerelated macular degeneration; two year results of the two prospective multicenter, controlled clinical trials. Ophthtalmology. 2006;113:1001-1006
  10. Package insert. Avastin (bevacizumab). San Francisco, CA: Genentech Inc., September 2006
  11. Goff MJ, Johnson RN, McDonald HR, et al.: Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina. 2007;27:432-438
  12. Spaide RF, Laud K, Fine HF, et al.: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390
  13. Feiner L, Barr EE, Shui YB, et al.: Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina. 2006;26:882-888
  14. Shahar J, Avery RL, Heilweil G, et al.: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).